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Abstract: Age-related macular degeneration (AMD) is one of the leading causes of blindness in
the United States, affecting approximately 11 million patients. AMD is caused primarily by an
upregulation of vascular endothelial growth factor (VEGF). In recent years, aflibercept injections have
been used to combat VEGF. However, this treatment requires frequent intravitreal injections, leading
to low patient compliance and several adverse side effects including scarring, increased intraocular
pressure, and retinal detachment. Polymeric nanoparticles have demonstrated the ability to deliver
a sustained release of drug, thereby reducing the necessary injection frequency. Aflibercept (AFL)
was encapsulated in poly lactic-co-glycolic acid (PLGA) nanoparticles (NPs) via double emulsion
diffusion. Scanning electron microscopy showed the NPs were spherical and dynamic light scattering
demonstrated that they were uniformly distributed (PDI < 1). The encapsulation efficiency and drug
loading were 75.76% and 7.76% respectively. In vitro release studies showed a sustained release of
drug; 75% of drug was released by the NPs in seven days compared to the full payload released in
24 h by the AFL solution. Future ocular in vivo studies are needed to confirm the biological effects
of the NPs. Preliminary studies of the proposed aflibercept NPs demonstrated high encapsulation
efficiency, a sustained drug release profile, and ideal physical characteristics for AMD treatment.
This drug delivery system is an excellent candidate for further characterization using an ocular
neovascularization in vivo model.
Keywords: age-related macular degeneration; vascular endothelial growth factor; aflibercept;
nanoparticles; PLGA

1. Introduction
A decrease in visual acuity can lead to alterations in the activities of daily living, quality of
life, self-care, and mental health of an individual. A disease commonly responsible for this visual
impairment is age-related macular degeneration (AMD). AMD is a degenerative disease of the macula
and it affects the part of the retina responsible for sharp, detailed central vision. AMD is the most
prominent cause of vision loss in people 50 years and older in North America and it is expected to
affect 7.5 million people by 2020 in the United States [1]. Several factors influence the prognosis and
progression of AMD, including genetic variation, living environment, and lifestyle [2].

Biomedicines 2018, 6, 92; doi:10.3390/biomedicines6030092

www.mdpi.com/journal/biomedicines

Biomedicines 2018, 6, 92

2 of 9

Neovascular or “wet” AMD accounts for more than 90% of individuals with advanced vision
loss. The distinctive feature of neovascular AMD is choroidal neovascularization (CNV), which is
regulated by growth factors including vascular endothelial growth factor (VEGF) [1]. In CNV there
is an abnormal proliferation of new blood vessels originating from the choroid, leading to sub- and
intra-retinal macular edema, fluid leakage, bleeding, and fibrosis of retinal tissue. This results in severe
visual deterioration [3].
Amongst the VEGF family of growth factors, VEGF-A is a signal protein that promotes
angiogenesis and vascular leakage in the retina. VEGF’s biological properties arise from binding
to trans-membrane VEGF receptors (VEGFR) on vascular endothelial cells. VEGF-A specifically binds
to VEGFR-1 in the process of inflammatory neovascularization [2]. However, VEGFR-2 is responsible
for triggering many of the proangiogenic functions of VEGF-A [4]. Drugs known as anti-VEGF agents
have been designed to block this binding of VEGF, thereby limiting its damage to the eye. To date,
the FDA has approved three anti-VEGF agents for ocular applications: Ranibizumab, pegaptanib,
and aflibercept [5]. Aflibercept (AFL) is a fusion protein containing both VEGFR-1 and VEGFR-2,
which binds to VEGF-A thus impeding its activity [2]. AFL’s prolonged duration of action is attributed
to its distinctive binding activity. By blocking the VEGF signal with AFL, it has been shown there is
stabilization and even reversal in the vision loss normally associated with neovascular AMD [3].
Many of the adverse effects of Anti-VEGF agents originate from their route of administration.
Intravitreal injections are perhaps the most common mode of administration to the posterior segment.
However, anti-VEGF agents possess a narrow therapeutic index, thereby necessitating frequent
injections to maintain an acceptable concentration of drug in the eye [6]. This frequency not only
reduces patient compliance, but also results in myriad potential adverse effects including retinal
detachment, vitreous hemorrhage, and increased intraocular pressure [7,8]. Ocular protein delivery has
the added challenges of short protein half-life and degradation by enzymes [9]. Polymeric nanoparticles
deliver a targeted sustained release of drug, thereby reducing the injection frequency and related
effects [10], as well as providing a therapeutic dose of protein with limited toxicity [11]. Furthermore,
nanoparticles have demonstrated the ability to localize on the retinal pigment epithelium (RPE),
an ideal trait for the amelioration of AMD [12].
Polymeric nanoparticles (NPs) can be prepared using various natural or synthetic materials.
Poly lactic-co-glycolic acid (PLGA) is a biodegradable synthetic polymer which is commonly used
for the preparation of NPs. The widespread use of PLGA in recent studies is partly due to its ability
to demonstrate a sustained drug release with a low cytotoxicity and minimal side effects [13,14].
PLGA can be used to encapsulate hydrophobic or hydrophilic materials and the shape and size of
PLGA NPs are easily manipulated [15]. For instance, Booysen et al. recently used PLGA to encapsulate
vancomycin in a nanoformulation. The NPs were 247 nm but did not possess uniformity when
analyzed under SEM. Regardless, the NPs were more effective in combating MRSA than a solution
of free vancomycin [16]. Sanchez et al. used PLGA microspheres to encapsulate the macromolecule
interferon-alpha (IFN-α). The sustained release and anti-proliferative activity of the microspheres
indicate that this is a suitable in vitro platform for macromolecule delivery [11]. Feczko et al. studied
the encapsulation of the protein bovine serum albumin (BSA) under various conditions. Using the
double emulsion solvent evaporation method, PLGA nanoparticles encapsulating the protein were
successfully produced with high encapsulation efficiencies [17]. Later, Swed et al. encapsulated
lysozyme and human transforming growth factor beta 1 (TGF-β1) separately in PLGA NPs to examine
protein encapsulation. They found that the NPs encapsulated at least 50% of each protein and possessed
both a uniform size distribution (PDI less than 0.2) and sustained release properties over 30 days.
Blank NPs were nontoxic to NIH3T3, HS68 and hATSC cells after 48 h; in fact the assay showed
significant cell proliferation with increasing concentrations of NPs [18]. It may therefore be concluded
that PLGA NPs are an appropriate mode of protein delivery.
There are several methods by which PLGA NPs can be produced. In this work, NPs containing
AFL (AFL-NPs) were prepared via double emulsion diffusion using the synthetic biodegradable
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2. Experimental Section
2. Experimental Section
2.1. Materials
2.1. Materials
Aflibercept (Eylea, 2 mg/0.05 mL) (Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA) was
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2.2. Nanoparticle Preparation
2.2. Nanoparticle Preparation
The double-emulsion diffusion method was used to prepare AFL NPs (Figure 1). One milligram
The double-emulsion diffusion method was used to prepare AFL NPs (Figure 1). One milligram
of AFL (25 µL stock solution) was added to 100 µL 1× PBS and a separate solution of 4.5 mg PLGA
of AFL (25 µL stock solution) was added to 100 µL 1× PBS and a separate solution of 4.5 mg PLGA
was prepared in 1 mL dichloromethane (DCM). These solutions were combined and emulsified using
was prepared in 1 mL dichloromethane (DCM). These solutions were combined and emulsified using
sonication at 9.5 W for approximately 30 s. After the dropwise addition of 2 mL 1% w/v PVA, the
sonication at 9.5 W for approximately 30 s. After the dropwise addition of 2 mL 1% w/v PVA,
suspension was emulsified via sonication at 9.5 W for another 30 s. The emulsion was stirred at 500
the suspension was emulsified via sonication at 9.5 W for another 30 s. The emulsion was stirred at
rpm overnight at 4 °C to◦ allow diffusion. The emulsion was split into two fractions and centrifuged
500 rpm overnight at 4 C to allow diffusion. The emulsion was split into two fractions and centrifuged
at 20,000× g at 4 °C
for 15 min. Each pellet was then resuspended in 1 mL 2% w/v mannitol. Blank
at 20,000× g at 4 ◦ C for 15 min. Each pellet was then resuspended in 1 mL 2% w/v mannitol. Blank NPs
NPs were prepared similarly excluding the addition of AFL.
were prepared similarly excluding the addition of AFL.

Figure 1. (A) Aflibercept nanoparticles were prepared via (B) the double emulsion diffusion method
(* aqueous
** organic
phase). were prepared via (B) the double emulsion diffusion method
Figure
1. (A)phase;
Aflibercept
nanoparticles

(* aqueous phase; ** organic phase).

2.3. Nanoparticle Characterization
The size and polydispersity index (PDI) of both the AFL and blank NPs were analyzed via
dynamic light scattering (DLS) using a Wyatt DynaPro plate reader (Wyatt Technology Corporation,
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2.3. Nanoparticle Characterization
The size and polydispersity index (PDI) of both the AFL and blank NPs were analyzed via
dynamic light scattering (DLS) using a Wyatt DynaPro plate reader (Wyatt Technology Corporation,
Santa Barbara, CA, USA). The NPs were diluted 1:200 in filtered deionized water to meet equipment
specifications and analyzed in triplicate.
2.4. Scanning Electron Microscopy (SEM)
The NPs were viewed via SEM using a JOEL JSM-6490LV (JOEL Industries, Tokyo, Japan).
Samples were diluted 1:10 in filtered deionized water and adhered to aluminum cylinders using a
carbon polymer adhesive. All images were obtained using a 5 kV acceleration voltage.
2.5. Encapsulation Efficiency and Drug Loading
The encapsulation efficiency (EE) and drug loading (DL) of the NP formulation was calculated
using the concentration of drug present in a 1 mL sample of the NPs. After centrifugation at 15,000× g
for 5 min, the NPs were suspended in methanol and placed at 4 ◦ C overnight to dissolve the NPs.
Both this sample and a standard curve of AFL in methanol were prepared using the Pierce BCA protein
assay (Thermo Scientific, Waltham, MA, USA) and analyzed via VIS spectroscopy at 562 nm on a
BioTek Synergy H4 plate reader (BioTek Instruments Inc., Winooski, VT, USA). The standard curve
was used to convert the absorbance of the NP sample to a concentration. EE and DL were calculated
as follows:
%EE = (Mass of entrapped drug)/(Total mass of drug) × 100%
%DL = (Mass of entrapped drug)/(Mass of entrapped drug + Mass of polymer) × 100%.
2.6. In Vitro Release Studies
An in vitro release study was conducted according to a previously reported method [19].
Dialysis membrane cassettes were soaked in 1× PBS at 4 ◦ C. Approximately 500 µL of AFL-NPs or
AFL solution were inserted into the membrane and suspended in 100 mL PBS at 37 ◦ C. Aliquots were
removed and replaced with preheated PBS at regular intervals over a period of seven days.
The collected samples were analyzed via BCA Protein Assay and read using spectroscopy at 562 nm
with the Synergy H4 plate reader (Biotek Industries, Inc., Winooski, VT, USA). These values were
compared to a calibration curve of AFL in 1× PBS to determine the cumulative percent of drug released
at each interval.
2.7. Cell Culture
Human retinal pigment epithelial (ARPE-19) cells (ATCC® CRL2302™) were grown in 1×
Dulbecco’s Modified Eagle’s Medium (DMEM) with 10% v/v fetal bovine serum (FBS). Cells were kept
in a Thermo Scientific Forma Steri-Cycle incubator (Fisher Scientific, Pittsburgh, PA, USA) at 37 ◦ C
and 5% carbon dioxide.
2.7.1. Cytotoxicity
The cytotoxicity of the AFL-loaded and blank NPs in ARPE-19 cells was measured using the
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide salt (MTT) assay [12]. ARPE-19 cells
were seeded in a 48-well plate and incubated at 37 ◦ C with 5% CO2 for 48 h to achieve confluence.
Cell culture media was aspirated and the cells were treated with each of the NP formulations at final
concentrations of 0.5 µM and 1 µM. After a 24-h incubation period, 300 µL of a 0.5 mg/mL solution
of MTT reagent previously prepared in DMEM were added to each well. After another four hours
of incubation, the MTT reagent was removed and 300 µL of DMSO were added to end the reaction.
After shaking briefly, the plate was analyzed at 570 nm using a BioTek Synergy H4 plate reader (BioTek
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Instruments Inc., Winooski, VT, USA) to determine the relative amounts of live cells present in
the
5 of 9
sample. These values were reported as a percentage of the untreated control.
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2.7.2. VEGF-A Inhibition
2.7.2. VEGF-A Inhibition
ARPE-19 cells were seeded in a 48-well plate and incubated at 37 °C
with 5% CO2 to achieve
ARPE-19 cells were seeded in a 48-well plate and incubated at 37 ◦ C with 5% CO2 to achieve
confluence and treated with each of the NP formulations at a final concentration of 0.5 µM. After 72 h,
confluence and treated with each of the NP formulations at a final concentration of 0.5 µM. After 72 h,
the expression of VEGF-A was quantified via enzyme-linked immunosorbent assay (ELISA) (Human
the expression of VEGF-A was quantified via enzyme-linked immunosorbent assay (ELISA) (Human
VEGFA ELISA kit, Thermo Scientific, Waltham, MA, USA). Media samples were collected and
VEGFA ELISA kit, Thermo Scientific, Waltham, MA, USA). Media samples were collected and analyzed
analyzed using the Synergy H4 plate reader (Biotek Industries, Inc., Winooski, VT, USA) at 450 nm
using the Synergy H4 plate reader (Biotek Industries, Inc., Winooski, VT, USA) at 450 nm and 550 nm.
and 550 nm. VEGF-A expression was calculated as follows:
VEGF-A expression was calculated as follows:
%Expression = (absorbance 450 nm − absorbance 550 nm)/(Control absorbance 450 nm −
%Expression = (absorbance 450 nm − absorbance 550 nm)/(Control absorbance 450 nm −
Control absorbance 550 nm) × 100%.
Control absorbance 550 nm) × 100%.
2.8.
2.8.Statistical
StatisticalAnalysis
Analysis
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Version5.02.
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concentrationofofNP
NPtreatment,
treatment,on
onboth
bothcell
cellviability
viabilityand
andVEGF-A
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with Bonferroni
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Results
3.3.Results
3.1.Nanoparticle
NanoparticleCharacterization
Characterization
3.1.
Thediameter
diameter and
and PDI
were
found
in triplicate
via DLS.
AFL-NPs
were
The
PDI of
of the
theAFL
AFLand
andblank
blankNPs
NPs
were
found
in triplicate
via DLS.
AFL-NPs
larger
than
their
respective
blanks
(Table
1).
The
PDI
was
consistently
less
than
1,
indicating
a
uniform
were larger than their respective blanks (Table 1). The PDI was consistently less than 1, indicating a
size distribution
(Figure 2A).
uniform
size distribution
(Figure 2A).
Table 1.
1. The
Thecharacteristics
characteristicsof
ofaflibercept
aflibercept NPs
NPs (n
(n ==3,3,mean
meanvalue
value±±SD).
SD).
Table
NP Type NP Type
Diameter
(nm) (nm)
Diameter
Blank
AFL-NPs

Blank
169.91 169.91
± 4.29± 4.29
AFL-NPs
243.13 ± 17.64

243.13 ± 17.64

PDI
PDI
%EE %EE %DL
0.050 ± 0.077
0.050 ± 0.077
0.201 ± 0.071 75.76 ± 2.59 7.76 ± 0.24
0.201 ± 0.071

75.76 ± 2.59

%DL
7.76 ± 0.24

Figure2.
2. AFL-NPs
forfor
(A)(A)
size size
distribution
and (B)
in vitro
Figure
AFL-NPs were
werecharacterized
characterized
distribution
and
(B) inrelease
vitro profile
releasecompared
profile
to
AFL
solution.
compared to AFL solution.

3.2. Scanning Electron Microscopy (SEM)
AFL and blank NPs were visualized using SEM (Figure 3). Inspection showed that the NPs were
spherical. The size and uniformity of the NPs corroborated with data determined via DLS.
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Figure 3.
3. SEM
SEM micrographs
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Figure
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Both images were obtained using 5 kV acceleration voltage.

3.3. Encapsulation Efficiency and Drug Loading
3.3. Encapsulation Efficiency and Drug Loading
The EE and DL of each NP formulation was determined via VIS spectroscopy after analysis
The EE and DL of each NP formulation was determined via VIS spectroscopy after analysis with
with the BCA protein assay. A standard curve of AFL in methanol was prepared to determine the
the BCA protein assay. A standard curve of AFL
in methanol was prepared to determine the
concentration of AFL present in the NP fraction (r2 = 0.9247) (not shown). The NPs demonstrated an
concentration of AFL present in the NP fraction (r2 = 0.9247) (not shown). The NPs demonstrated an
EE of 75.76 ± 2.59% and DL of 7.76 ± 0.24% (Table 1).
EE of 75.76 ± 2.59% and DL of 7.76 ± 0.24% (Table 1).
3.4. In Vitro Release
3.4. In Vitro Release
The rate of drug release from the NP formulation versus AFL in free solution was examined over
rate
drug
formulation
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in free solution
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mLrelease
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the NPs released 74.49% in seven days. An initial burst release is demonstrated from the NPs in the
the
released2B).
74.49% in seven days. An initial burst release is demonstrated from the NPs in the
firstNPs
2 h (Figure
first 2 h (Figure 2B).
3.5. Cytotoxicity
3.5. Cytotoxicity
The cytotoxicity of blank NPs, AFL NPs and AFL solution to ARPE-19 cells were determined via
cytotoxicity
blank0.5
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solution
to ARPE-19
cells wereindetermined
via
MTTThe
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After 24 of
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µMAFL
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andAFL
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cell viability
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by
30.11
±
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±
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reduction
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AFL. The 1 µM treatments of AFL NPs and blank NPs resulted in a 41.29 ± 10.99% and 40.87 ± 7.15%
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NPs However,
(Figure 4A).
loaded NPs showed no significant difference in cytotoxicity compared to the blank NPs (Figure 4A).
3.6. VEGF-A Inhibition
3.6. VEGF-A Inhibition
The effect of AFL and AFL NPs on the VEGF-A expression of ARPE-19 cells was examined
via ELISA.
After
72 h,and
VEGF-A
was
reducedofby
0.5 µMcells
AFLwas
solution
or AFL
The effect
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Figure 4. (A) AFL solution was non-toxic. AFL-NPs demonstrated similar cytotoxicity in ARPE-19
Figure 4. (A) AFL solution was non-toxic. AFL-NPs demonstrated similar cytotoxicity in ARPE-19
cells to blank NPs (n = 3, mean value ± SD); (B) after 72 h, VEGF-A expression by ARPE-19 cells was
cells to blank NPs (n = 3, mean value ± SD); (B) after 72 h, VEGF-A expression by ARPE-19 cells was
reduced post-treatment (0.5 µM) with AFL and AFL NPs (n = 3, mean ± SD).
reduced post-treatment (0.5 µM) with AFL and AFL NPs (n = 3, mean ± SD).

4. Discussion
4. Discussion
The double emulsion diffusion method was used to prepare AFL NPs. Particle size data revealed
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PLGA NPs formulated by Patel et al. illustrated a similar in vitro release profile with 25% of drug
acetonide. More potent inhibitory properties were demonstrated after 72 h compared to 12 h of
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released after 48 h [25]. These sustained release properties allow the NPs to deliver a more powerful
effect in vivo.
The current study demonstrates the potential of a novel nanoformulation containing AFL for the
inhibition of VEGF in vitro. Further in vitro studies will be needed to demonstrate VEGF inhibition
by the nanoformulation as well as AFL solution. Future in vivo studies will be carried out in a
laser-induced choroidal neovascularization mouse model. The efficacy, toxicity, biodistribution and
pharmacokinetics will be examined in this manner. Further clinical studies may be conducted
in a human population to analyze the total effect of the nanoformulation. In summary, our
nanoformulation of AFL shows potential as a protein drug delivery vehicle for the amelioration
of ocular neovascularization in vitro.
5. Conclusions
Polymeric NPs were prepared for the sustained delivery of the protein aflibercept. The NPs
were approximately 200 nm in diameter; an appropriate size for ocular therapeutics. The NPs were
uniformly distributed and possessed a spherical morphology. The NPs demonstrated a sustained
drug release over seven days and were not significantly more toxic to ARPE-19 cells than similarly
prepared blank NPs. VEGF-A reduction in ARPE-19 cells was not significant after 72 h due to the
sustained release property of the NPs. Future in vivo studies are needed to determine the effect of the
NPs on live animal tissue as well as the clinical viability of the NPs in humans. Overall, aflibercept
NPs demonstrated promising properties as a protein delivery vehicle for the future treatment of AMD
and other neovascular conditions.
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